July 11, 2012

July 11, 2012
How Will New Science Impact the US
National HIV/AIDS Strategy?


Welcome to another day in my life. Today is Wednesday and we have almost made it through the middle of another work week. I hope you are having a safe and great week so far. It is another busy week for Dab the AIDS Bear and me.

There have been several articles in the news lately about HIV. If you are going to the International AIDS Conference in July this month, they are going to be discussing this issue about how new science will impact the US national HIV/AIDS strategy.

AIDS 2012 Conference Satellite - Free and open to the public

RSVP requested

Sunday, July 22, 2012, 11:15 AM -1:15 PM

Mini Room 4, Walter E. Washington Convention Center, Washington, DC

Hosted by the Coalition for a National HIV/AIDS Strategy

Moderator: Gregorio Millett, Senior Scientist, CDC/HHS Liaison to White House Office of National AIDS Policy

Presenters include (list still in formation):

Carlos del Rio, MD, Hubert Professor and Chair, Hubert Department of Global Health, Emory University: Treatment Cascade


Keith R. Green, MSW, Director of Federal Affairs, AIDS Foundation of Chicago: PrEP and the NHAS


David R. Holtgrave, PhD, Chair, Department of Health Behavior and Society, Johns Hopkins Bloomberg School of Public Health: Costs, Consequences and Feasibility of Achieving the NHAS Goals


Molly Morgan Jones, PhD, Senior Analyst, RAND Europe: Mapping Pathways: Exploring strategies in the use of ARV-based prevention

To register go to: http://wfc2.wiredforchange.com/o/8810/p/salsa/event/common/public/?event_KEY=70824

The U.S. National HIV/AIDS Strategy (NHAS) has been in place for two years, and since its release, scientific breakthroughs and new research have transformed our thinking about the US HIV epidemic. HPTN 052 and successful PrEP and microbicide trials demonstrate that biomedical interventions hold promise that were unthinkable just 2 years ago.

At the same time, Gardner and his coauthors shine a spotlight on the human factors impacting the epidemic-half of people with HIV are not in medical care, and just 1 in 4 achieves treatment success. Key researchers, including some who contributed to these breakthrough findings, will weigh in on the implications of new research on the US strategy.

Click here to register.

This session will be immediately followed by the satellite session, "Achieving the Goals of the United States National HIV/AIDS Strategy: Next steps", organized by the U.S. Department of Health and Human Services. The satellite will take place at 1:30 p.m. in session room 9.

This symposium is conducted in collaboration with and funded by Bristol-Myers Squibb with no editorial review of content.

Hope you have a great hump day!

Until we meet again; here's wishing you health, hope, happiness and just enough.

big bear hug,



Daddy Dab